Kidney International Reports最新文献

英文中文

Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium 骨质疏松症和ckd代谢性骨病在同一保护伞下：来自联合科学研讨会的见解

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-05-01 Epub Date: 2026-02-17 DOI: 10.1016/j.ekir.2026.106362

David W. Dempster , Pieter Evenepoel , Thomas L. Nickolas , Ziad A. Massy , Sandro Mazzaferro , Nicholas C. Harvey , Paul D. Miller , Michael Pazianas

Osteoporosis and chronic kidney disease (CKD)–metabolic bone disease (MBD) (CKD-MBD) are increasingly recognized as overlapping conditions, particularly in the aging population. Declining renal function and skeletal fragility often coexist, because CKD-MBD may develop in a skeleton already compromised by preexisting osteoporosis. Adynamic bone, often resulting from excessive suppression of parathyroid hormone (PTH) and now a common form of renal osteodystrophy (ROD), may histologically resemble low-turnover osteoporosis; distinguishing between the 2 under light microscopy remains difficult, and reliable differentiation often depends on clinical context. Nevertheless, nephrologists and nonnephrologist bone specialists frequently work in parallel rather than in collaboration.This separation has contributed to persistent diagnostic gaps and fragmented management, especially in patients with advanced CKD. Advances in imaging, biochemical markers, and bone histomorphometry have improved insight into disease mechanisms; however, limitations in current diagnostic approaches remain. Osteoporosis therapies are frequently underused in CKD, despite growing evidence supporting efficacy and safety across a broader range of kidney function than previously assumed. Despite efforts to refine the definition of osteoporosis beyond bone mineral density (BMD) alone, clinical misclassification continues.Beyond skeletal health, vascular calcification (VC)—driven by disordered calcium–phosphate homeostasis—remains insufficiently prioritized in clinical decision-making, despite its strong association with cardiovascular morbidity and mortality in CKD. Emerging concepts, such as intermittent PTH administration, an established treatment in osteoporosis, illustrate the potential for interventions that may restore mineral balance and improve skeletal integrity in selected CKD populations. Whether such strategies can also favorably influence cardiovascular risk remains uncertain and warrant investigation. This integrated framework may improve interdisciplinary care.

骨质疏松症和慢性肾脏疾病(CKD) -代谢性骨病（MBD）（CKD-MBD）越来越被认为是重叠的疾病，特别是在老龄化人群中。肾功能下降和骨骼脆弱经常共存，因为CKD-MBD可能在已经存在骨质疏松症的骨骼中发展。动态骨通常由甲状旁腺激素（PTH）的过度抑制引起，现在是肾性骨营养不良（ROD）的一种常见形式，在组织学上可能类似于低周转率骨质疏松症；在光镜下区分两者仍然很困难，可靠的区分往往取决于临床情况。然而，肾脏学家和非肾脏学家的骨骼专家经常并行工作，而不是合作。这种分离导致了持续的诊断差距和分散的管理，特别是在晚期CKD患者中。影像学、生化标志物和骨组织形态计量学的进步提高了对疾病机制的认识；然而，目前的诊断方法仍然存在局限性。尽管越来越多的证据支持骨质疏松治疗在更广泛的肾功能范围内的有效性和安全性，但骨质疏松治疗在CKD中经常使用不足。尽管努力完善骨质疏松症的定义，而不仅仅是骨矿物质密度（BMD），但临床错误分类仍在继续。除了骨骼健康之外，尽管血管钙化（VC）与慢性肾病的心血管发病率和死亡率密切相关，但由磷酸钙稳态失调驱动的血管钙化（VC）在临床决策中仍未得到充分重视。新出现的概念，如间歇性给药甲状旁腺激素，骨质疏松症的既定治疗方法，说明了在特定CKD人群中恢复矿物质平衡和改善骨骼完整性的干预潜力。这些策略是否也能积极影响心血管风险仍不确定，需要进一步调查。这一综合框架可以改善跨学科护理。

{"title":"Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium","authors":"David W. Dempster , Pieter Evenepoel , Thomas L. Nickolas , Ziad A. Massy , Sandro Mazzaferro , Nicholas C. Harvey , Paul D. Miller , Michael Pazianas","doi":"10.1016/j.ekir.2026.106362","DOIUrl":"10.1016/j.ekir.2026.106362","url":null,"abstract":"<div><div>Osteoporosis and chronic kidney disease (CKD)–metabolic bone disease (MBD) (CKD-MBD) are increasingly recognized as overlapping conditions, particularly in the aging population. Declining renal function and skeletal fragility often coexist, because CKD-MBD may develop in a skeleton already compromised by preexisting osteoporosis. Adynamic bone, often resulting from excessive suppression of parathyroid hormone (PTH) and now a common form of renal osteodystrophy (ROD), may histologically resemble low-turnover osteoporosis; distinguishing between the 2 under light microscopy remains difficult, and reliable differentiation often depends on clinical context. Nevertheless, nephrologists and nonnephrologist bone specialists frequently work in parallel rather than in collaboration.This separation has contributed to persistent diagnostic gaps and fragmented management, especially in patients with advanced CKD. Advances in imaging, biochemical markers, and bone histomorphometry have improved insight into disease mechanisms; however, limitations in current diagnostic approaches remain. Osteoporosis therapies are frequently underused in CKD, despite growing evidence supporting efficacy and safety across a broader range of kidney function than previously assumed. Despite efforts to refine the definition of osteoporosis beyond bone mineral density (BMD) alone, clinical misclassification continues.Beyond skeletal health, vascular calcification (VC)—driven by disordered calcium–phosphate homeostasis—remains insufficiently prioritized in clinical decision-making, despite its strong association with cardiovascular morbidity and mortality in CKD. Emerging concepts, such as intermittent PTH administration, an established treatment in osteoporosis, illustrate the potential for interventions that may restore mineral balance and improve skeletal integrity in selected CKD populations. Whether such strategies can also favorably influence cardiovascular risk remains uncertain and warrant investigation. This integrated framework may improve interdisciplinary care.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106362"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology 将孟德尔随机化从传统的危险因素转移到肾脏病药物开发和临床试验的分子靶点

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-05-01 Epub Date: 2026-02-12 DOI: 10.1016/j.ekir.2026.106350

Abigail J. Berube , Eryn Yu , Pukhraj S. Gaheer , Matthew B. Lanktree

Mendelian randomization leverages the random assortment of alleles at conception to investigate how genetically mediated changes in an exposure affect an outcome while minimizing concerns related to reverse causation and unmeasured confounding. Initially applied to assess the causal impact of modifiable traditional risk factors as mediators of disease risk, Mendelian randomization studies now incorporate large-scale multiomic datasets providing valuable insights for drug target discovery. By analyzing cis genetic changes that affect gene activity or protein levels—using advancing techniques like single-cell sequencing and proteomics—Mendelian randomization can identify new therapeutic targets, predict drug target efficacy and effect size before trial development, anticipate adverse effects, reduce late-stage trial failures, and identify opportunities for drug repurposing. This review explains the basic principles, broad applications, and inherent limitations of Mendelian randomization in drug-target identification, validation, and repurposing within the context of kidney disease. Many retrospective examples of concordant conclusions from clinical trials and Mendelian randomization studies have been reported including statins, allopurinol, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Genetic evidence should now be prospectively evaluated for all drugs attempting to traverse the “translational valley of death” in drug development. We summarize current examples, spotlight emerging analytic methodologies such as phenome-wide Mendelian randomization and integrated multiomics, and discuss future directions to accelerate drug development in nephrology.

孟德尔随机化利用受孕时等位基因的随机分类来研究暴露中基因介导的变化如何影响结果，同时最大限度地减少与反向因果关系和不可测量的混杂相关的担忧。孟德尔随机化研究最初用于评估可改变的传统风险因素作为疾病风险介质的因果影响，现在纳入了大规模的多组学数据集，为药物靶点发现提供了有价值的见解。通过分析影响基因活性或蛋白质水平的顺式基因变化——使用单细胞测序和蛋白质组学等先进技术——孟德尔随机化可以确定新的治疗靶点，在试验开发之前预测药物靶点疗效和效应大小，预测副作用，减少后期试验失败，并确定药物再利用的机会。这篇综述解释了孟德尔随机化在肾脏疾病的药物靶点识别、验证和再利用中的基本原理、广泛应用和固有局限性。许多回顾性的临床试验和孟德尔随机化研究得出了一致的结论，包括他汀类药物、别嘌呤醇、钠-葡萄糖共转运蛋白-2 （SGLT2）抑制剂和胰高血糖素样肽-1 （GLP-1）受体激动剂。现在应该对所有试图穿越药物开发“死亡转化谷”的药物进行前瞻性的遗传证据评估。我们总结了目前的例子，重点介绍了新兴的分析方法，如全表型孟德尔随机化和集成多组学，并讨论了加速肾病学药物开发的未来方向。

{"title":"Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology","authors":"Abigail J. Berube , Eryn Yu , Pukhraj S. Gaheer , Matthew B. Lanktree","doi":"10.1016/j.ekir.2026.106350","DOIUrl":"10.1016/j.ekir.2026.106350","url":null,"abstract":"<div><div>Mendelian randomization leverages the random assortment of alleles at conception to investigate how genetically mediated changes in an exposure affect an outcome while minimizing concerns related to reverse causation and unmeasured confounding. Initially applied to assess the causal impact of modifiable traditional risk factors as mediators of disease risk, Mendelian randomization studies now incorporate large-scale multiomic datasets providing valuable insights for drug target discovery. By analyzing <em>cis</em> genetic changes that affect gene activity or protein levels—using advancing techniques like single-cell sequencing and proteomics—Mendelian randomization can identify new therapeutic targets, predict drug target efficacy and effect size before trial development, anticipate adverse effects, reduce late-stage trial failures, and identify opportunities for drug repurposing. This review explains the basic principles, broad applications, and inherent limitations of Mendelian randomization in drug-target identification, validation, and repurposing within the context of kidney disease. Many retrospective examples of concordant conclusions from clinical trials and Mendelian randomization studies have been reported including statins, allopurinol, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Genetic evidence should now be prospectively evaluated for all drugs attempting to traverse the “translational valley of death” in drug development. We summarize current examples, spotlight emerging analytic methodologies such as phenome-wide Mendelian randomization and integrated multiomics, and discuss future directions to accelerate drug development in nephrology.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106350"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection” [Kidney International Reports Volume 10, Issue 9, September 2025, Pages 3225-3238] “定义肾脏移植抗体介导的排斥反应测试之间的关系”的勘误表[肾脏国际报告第10卷，第9期，2025年9月，页3225-3238]

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-05-01 Epub Date: 2026-02-26 DOI: 10.1016/j.ekir.2026.106407

Katelynn S. Madill-Thomsen , Luis G. Hidalgo , Zachary P. Demko , Philippe M. Gauthier , Adam Prewett , Dave Lowe , Jessica J. Chang , Martina Mackova , Klemens Budde , Jonathan S. Bromberg , Philip F. Halloran , Trifecta-Kidney Study Group

引用次数: 0

Prevention of Recurrent Kidney Stones: A CARI Guidelines Summary 预防肾结石复发：CARI指南总结

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-05-01 Epub Date: 2026-02-09 DOI: 10.1016/j.ekir.2026.106346

David J. Tunnicliffe , Lyn Lloyd , Adam Mullan , Andrew J. Mallett , Ieuan Wickham , Nadya York , Mia E. Abdy , Brydee Cashmore , Hicham Cheikh Hassan , Matthew Jose

Introduction

The incidence of kidney stones is increasing in Australia and Aotearoa New Zealand, increasing pressure on emergency departments for acute pain management and stretching nephrology and dietetics services tasked with preventing recurrence. To address this, the Caring for Australians and New ZealandeRs with kidney Impairment (CARI) guidelines provide evidence-based recommendations that complement urological and surgical care, contextualized for our region and developed with input from people with lived experience.

Methods

Guidelines were developed through a 5-stage process aligned with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. A multidisciplinary working group formulated Population Intervention/Exposure Comparator Outcome Methodology questions, and a group of consumers in a dedicated workshop scoped guideline topics. A systematic literature review was conducted, prioritizing high-quality evidence that was critically appraised and synthesized. Recommendations were drafted using the GRADE Evidence-to-Decision framework, incorporating perspectives of lived experience throughout.

Results

These guidelines provide recommendations on the diagnosis, metabolic evaluation, and management to prevent recurrent kidney stones. Nutrition therapy provided by dietitians with expertise is a fundamental and cost-effective intervention for preventing recurrent kidney stones. Although nutrition therapy should precede pharmacological interventions in most cases, the use of potassium citrate and thiazide diuretics may be considered when nutrition therapy alone is insufficient.

Conclusion

These CARI guidelines address a critical gap in the management of kidney stones in Australia and New Zealand by providing evidence-based, contextualized recommendations to support nephrologists, dietitians with expertise in kidney stones, and other health professionals in delivering consistent, high-quality care that reduces kidney stone recurrence and improves outcomes.

在澳大利亚和新西兰，肾结石的发病率正在上升，这增加了急诊部门在急性疼痛管理方面的压力，并扩大了肾脏病学和营养学服务的范围，以防止复发。为了解决这一问题，《澳大利亚和新西兰肾脏损害患者护理指南》（CARI）提供了基于证据的建议，以补充泌尿外科护理，为本地区提供了背景，并根据有生活经验的人的意见进行了发展。方法：指南是根据建议分级、评估、发展和评估（GRADE）方法，通过5个阶段的过程制定的。一个多学科工作组制定了人口干预/暴露比较结果方法学问题，一组消费者在专门的研讨会上制定了指南主题。进行了系统的文献综述，优先考虑经过严格评价和综合的高质量证据。建议是使用GRADE从证据到决策的框架起草的，贯穿了生活经验的观点。结果本指南对肾结石的诊断、代谢评价和防治提供了建议。由专业营养师提供的营养治疗是预防肾结石复发的基本和经济有效的干预措施。虽然在大多数情况下，营养治疗应先于药物干预，但当单独的营养治疗不足时，可以考虑使用柠檬酸钾和噻嗪类利尿剂。结论：这些CARI指南解决了澳大利亚和新西兰在肾结石管理方面的一个关键差距，提供了基于证据的、情境化的建议，以支持肾病学家、肾结石专业营养师和其他卫生专业人员提供一致的、高质量的护理，减少肾结石复发并改善预后。

{"title":"Prevention of Recurrent Kidney Stones: A CARI Guidelines Summary","authors":"David J. Tunnicliffe , Lyn Lloyd , Adam Mullan , Andrew J. Mallett , Ieuan Wickham , Nadya York , Mia E. Abdy , Brydee Cashmore , Hicham Cheikh Hassan , Matthew Jose","doi":"10.1016/j.ekir.2026.106346","DOIUrl":"10.1016/j.ekir.2026.106346","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of kidney stones is increasing in Australia and Aotearoa New Zealand, increasing pressure on emergency departments for acute pain management and stretching nephrology and dietetics services tasked with preventing recurrence. To address this, the Caring for Australians and New ZealandeRs with kidney Impairment (CARI) guidelines provide evidence-based recommendations that complement urological and surgical care, contextualized for our region and developed with input from people with lived experience.</div></div><div><h3>Methods</h3><div>Guidelines were developed through a 5-stage process aligned with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. A multidisciplinary working group formulated Population Intervention/Exposure Comparator Outcome Methodology questions, and a group of consumers in a dedicated workshop scoped guideline topics. A systematic literature review was conducted, prioritizing high-quality evidence that was critically appraised and synthesized. Recommendations were drafted using the GRADE Evidence-to-Decision framework, incorporating perspectives of lived experience throughout.</div></div><div><h3>Results</h3><div>These guidelines provide recommendations on the diagnosis, metabolic evaluation, and management to prevent recurrent kidney stones. Nutrition therapy provided by dietitians with expertise is a fundamental and cost-effective intervention for preventing recurrent kidney stones. Although nutrition therapy should precede pharmacological interventions in most cases, the use of potassium citrate and thiazide diuretics may be considered when nutrition therapy alone is insufficient.</div></div><div><h3>Conclusion</h3><div>These CARI guidelines address a critical gap in the management of kidney stones in Australia and New Zealand by providing evidence-based, contextualized recommendations to support nephrologists, dietitians with expertise in kidney stones, and other health professionals in delivering consistent, high-quality care that reduces kidney stone recurrence and improves outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106346"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding Kidney Care: How Nonphysician Health Workers Can Address the Global CKD Crisis 扩大肾脏护理：非医师卫生工作者如何应对全球CKD危机

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-03-01 Epub Date: 2025-10-04 DOI: 10.1016/j.ekir.2025.09.037

C. Elena Cervantes , Daniel V. O’Hara , Ana Catalina Alvarez-Elias , Yogeshni Chandra , Marek Kollar , Tae Won Yi , Rasha Hussein , Mythri Shankar , Priti Meena , Becky Mingyao Ma , Chimezie Godswill Okwuonu , Vivekanand Jha

The current global nephrology workforce is insufficient to meet the increasing burden of chronic kidney disease (CKD) and kidney failure. Nonphysician health workers (NPHWs) may be well-placed to fill the gap and deliver guideline-aligned care. We review the range of NPHW categories and care models that could be enlisted in different health care settings; the range of contributions that could be made for CKD prevention, education, screening, management, and monitoring; the existing and required resources to support NPHWs; and technological advancements that can help alleviate the workload. Through analysis of collaborative approaches and existing alternative care delivery models, we aimed to provide insights into how such programs can be successfully implemented to augment the existing health workforce to deliver effective care and improve outcomes of people with and at risk of developing kidney disease worldwide.

目前全球肾脏病人力资源不足以满足慢性肾脏疾病（CKD）和肾衰竭日益增加的负担。非医师卫生工作者（nphw）可以很好地填补这一空白，并提供与指南一致的护理。我们回顾了NPHW的类别和护理模式的范围，可以在不同的卫生保健机构；CKD预防、教育、筛查、管理和监测方面的贡献范围；现有及所需的资源，以支援非卫生工作者；技术进步可以帮助减轻工作量。通过对合作方法和现有替代医疗服务模式的分析，我们旨在深入了解如何成功实施这些项目，以增加现有的卫生人力，提供有效的护理，改善全球肾病患者和有患肾病风险的人的预后。

{"title":"Expanding Kidney Care: How Nonphysician Health Workers Can Address the Global CKD Crisis","authors":"C. Elena Cervantes , Daniel V. O’Hara , Ana Catalina Alvarez-Elias , Yogeshni Chandra , Marek Kollar , Tae Won Yi , Rasha Hussein , Mythri Shankar , Priti Meena , Becky Mingyao Ma , Chimezie Godswill Okwuonu , Vivekanand Jha","doi":"10.1016/j.ekir.2025.09.037","DOIUrl":"10.1016/j.ekir.2025.09.037","url":null,"abstract":"<div><div>The current global nephrology workforce is insufficient to meet the increasing burden of chronic kidney disease (CKD) and kidney failure. Nonphysician health workers (NPHWs) may be well-placed to fill the gap and deliver guideline-aligned care. We review the range of NPHW categories and care models that could be enlisted in different health care settings; the range of contributions that could be made for CKD prevention, education, screening, management, and monitoring; the existing and required resources to support NPHWs; and technological advancements that can help alleviate the workload. Through analysis of collaborative approaches and existing alternative care delivery models, we aimed to provide insights into how such programs can be successfully implemented to augment the existing health workforce to deliver effective care and improve outcomes of people with and at risk of developing kidney disease worldwide.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103625"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145929212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting Vincristine for FSGS: Proof-of-Mechanism Arrives, but Whom Should We Treat? 重新审视长春新碱治疗FSGS：机制证明到来，但我们应该治疗谁？

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-03-01 Epub Date: 2025-12-24 DOI: 10.1016/j.ekir.2025.103749

Wenjie Guo , Jie Luo , Zhixiao Li , Xue Li , Yingying Zhang , Jingyi Yang

引用次数: 0

Corrigendum to “Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy” [Kidney International Reports Volume 10, Issue 11, November 2025, Pages 3785-3795] “减少剂量周期性皮质类固醇和环磷酰胺对原发性膜性肾病疗效的随机对照试验”的勘误表[肾脏国际报告第10卷，第11期，2025年11月，第3785-3795页]

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-03-01 Epub Date: 2026-01-23 DOI: 10.1016/j.ekir.2025.103768

Raja Ramachandran , Prabhat Chauhan , Joyita Bharati , Manisha Sahay , Indranil Ghosh , Vivek Sood , Thakur Sain , Prabhjot Kaur , Vinod Kumar , Arun Prabhahar , Ritambhra Nada , Jasmine Sethi , Smita Divyaveer , Manish Rathi , Harbir Kohli , Vivekanand Jha

引用次数: 0

Rescue Therapy With Pegcetacoplan in a Patient With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits Pegcetacoplan对单克隆免疫球蛋白沉积的增生性肾小球肾炎患者的抢救治疗

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-03-01 Epub Date: 2026-01-08 DOI: 10.1016/j.ekir.2026.103770

Hormaz Dastoor , Emad Khater , Suhail Al Salam , Stephen G. Holt

引用次数: 0

Long-Term Outcomes of IgM-Positive Plasma Cell Tubulointerstitial Nephritis igm阳性浆细胞小管间质性肾炎的长期预后

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-03-01 Epub Date: 2026-01-06 DOI: 10.1016/j.ekir.2025.103764

Naoki Takahashi , Haruyoshi Yoshida , Hideki Kimura , Chie Yamamoto , Makoto Yamamoto , Nanami Iwamura , Kohei Matsuta , Sho Nishikawa , Kazuhisa Nishimori , Sachiko Fukushima , Yudai Nishikawa , Mamiko Kobayashi , Kenji Kasuno , Hironobu Naiki , Masayuki Iwano , Tadashi Toyama

引用次数: 0

SGLT2 Inhibitors and Long-Term Outcomes After AKI SGLT2抑制剂和AKI后的长期预后。

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2026-03-01 Epub Date: 2025-12-31 DOI: 10.1016/j.ekir.2025.103752

Anyarin Wannakittirat , Veerapatr Nimkietkajorn , Peerapat Thanapongsathorn , Weerachai Chaijamorn , Nattira Sorose , Akarathep Leewongworasingh , Khanitha Yimsangyad , Nuttha Lumlertgul , Sadudee Peerapornratana , Nattachai Srisawat

Introduction

Currently, there is no specific treatment for post–acute kidney injury (AKI) survivors, one of the highest risk groups of the renal and nonrenal adverse long-term outcomes. This study aimed to determine whether the sodium-glucose cotransporter-2 inhibitor (SGLT2i) can decrease 1-year major adverse kidney events (MAKE365) in post-AKI setting.

Methods

Multicenter randomized controlled trial, involving severe AKI survivors from 3 tertiary care hospitals, who were dialysis independent, and had an estimated glomerular filtration rate (eGFR) ≥ 20 ml/min per 1.73 m². The participants were randomized to receive empagliflozin 10 mg/d or matching placebo for 1 year after the incident AKI. The primary outcome was MAKE365, defined as a composite of persistent kidney dysfunction (a sustained decrease in eGFR ≥ 25% or increase in serum creatinine ≥ 200% of baseline), the need for long-term dialysis, or death at 1 year after the incident of AKI.

Results

A total of 200 participants were included in this study, 98 patients in empagliflozin group and 102 patients in placebo group; AKI stage 3 was predominant, with renal replacement therapy required for 30% and 23% of patients in each group, respectively. On modified intention-to-treat analysis, MAKE365 occurred in 35% in the empagliflozin group and 36% in the placebo group (P = 0.82). The incident rate ratio indicated a significant reduction in recurrent AKI in the empagliflozin group (34 vs. 66 per 100 person-years, respectively; incident rate ratio: 0.51, 95% confidence interval [CI]: 0.31–0.84; P = 0.008).

Conclusion

Empagliflozin could not show reduction in MAKE365 but showed potential benefits in reducing recurrent AKI.

急性肾损伤（AKI）后幸存者是肾脏和非肾脏不良长期结局的高危人群之一，目前尚无专门的治疗方法。本研究旨在确定钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i）是否可以减少aki后1年的主要肾脏不良事件（MAKE365）。方法：多中心随机对照试验，纳入来自3家三级医院的严重AKI幸存者，他们不需要透析，估计肾小球滤过率(eGFR)≥20ml /min / 1.73 m2。在AKI事件发生后1年内，参与者被随机分配接受恩格列净10mg /d或匹配的安慰剂。主要终点为MAKE365，定义为持续性肾功能不全（eGFR持续下降≥25%或血清肌酐升高≥基线的200%）、需要长期透析或AKI发生后1年死亡的综合指标。结果：本研究共纳入200例受试者，恩格列净组98例，安慰剂组102例；AKI 3期占主导地位，两组分别有30%和23%的患者需要肾脏替代治疗。在修改意向治疗分析中，恩格列净组的MAKE365发生率为35%，安慰剂组为36% （P = 0.82）。发生率比表明，恩格列净组复发性AKI发生率显著降低（分别为34 vs 66 / 100人-年；发生率比：0.51,95%可信区间[CI]: 0.31-0.84; P = 0.008）。结论：恩帕列净不能降低MAKE365，但对减少复发性AKI有潜在的益处。

{"title":"SGLT2 Inhibitors and Long-Term Outcomes After AKI","authors":"Anyarin Wannakittirat , Veerapatr Nimkietkajorn , Peerapat Thanapongsathorn , Weerachai Chaijamorn , Nattira Sorose , Akarathep Leewongworasingh , Khanitha Yimsangyad , Nuttha Lumlertgul , Sadudee Peerapornratana , Nattachai Srisawat","doi":"10.1016/j.ekir.2025.103752","DOIUrl":"10.1016/j.ekir.2025.103752","url":null,"abstract":"<div><h3>Introduction</h3><div>Currently, there is no specific treatment for post–acute kidney injury (AKI) survivors, one of the highest risk groups of the renal and nonrenal adverse long-term outcomes. This study aimed to determine whether the sodium-glucose cotransporter-2 inhibitor (SGLT2i) can decrease 1-year major adverse kidney events (MAKE365) in post-AKI setting.</div></div><div><h3>Methods</h3><div>Multicenter randomized controlled trial, involving severe AKI survivors from 3 tertiary care hospitals, who were dialysis independent, and had an estimated glomerular filtration rate (eGFR) ≥ 20 ml/min per 1.73 m<sup>2</sup>. The participants were randomized to receive empagliflozin 10 mg/d or matching placebo for 1 year after the incident AKI. The primary outcome was MAKE365, defined as a composite of persistent kidney dysfunction (a sustained decrease in eGFR ≥ 25% or increase in serum creatinine ≥ 200% of baseline), the need for long-term dialysis, or death at 1 year after the incident of AKI.</div></div><div><h3>Results</h3><div>A total of 200 participants were included in this study, 98 patients in empagliflozin group and 102 patients in placebo group; AKI stage 3 was predominant, with renal replacement therapy required for 30% and 23% of patients in each group, respectively. On modified intention-to-treat analysis, MAKE365 occurred in 35% in the empagliflozin group and 36% in the placebo group (<em>P</em> = 0.82). The incident rate ratio indicated a significant reduction in recurrent AKI in the empagliflozin group (34 vs. 66 per 100 person-years, respectively; incident rate ratio: 0.51, 95% confidence interval [CI]: 0.31–0.84; <em>P</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>Empagliflozin could not show reduction in MAKE365 but showed potential benefits in reducing recurrent AKI.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103752"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Kidney International Reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀